KFDA approves Avodart, BPH drug

Published: 2004-04-30 06:57:00

Updated: 2004-04-30 06:57:00

GSK has received its approval in Korea for Avodart (dutasteride), the oral medicine for treating benign prostatic hyperplasia (BPH) in men.

Dutasteride inhibits 5-alpha-reductase, blocking the formation of the hormone dihydrotestosterone (DHT). DHT is produced from testosterone by 5-alpha-red...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK